Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans

Endokrynologia Polska

Volumn 58, Issue 3, 2007, Pages 188-194

  Marcinkowska, Magdalena ^a   Lewandowski, Krzysztof C ^a,b   Lewinski, Andrzej ^a   Bienkiewicz, Malgorzata ^a   Basinska Lewandowska, Magdalena ^a   Salata, Ireneusz ^a   Randeva, Harpal S ^b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Dexamethasone; Glucose tolerance; Insulin resistance; Visfatin

Indexed keywords

DEXAMETHASONE; INSULIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; DEXAMETHASONE; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE;

EID: 38449117417     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Fukuhara A, Matsuda M, Nishizawa M et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 2005; 307: 426-430.
2. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556.
3. Spranger J, Kroke A, Möhlig M et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003; 361: 226-228.
4. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hypoinsulinemia. J Clin Endocrinol Metab 2001; 86: 1930-1935.
5. Berndt J, Klöting N, Kralisch S et al. Plasma visfatin concentrations and fat-Specific mRNA expression in humans. Diabetes 2005; 54: 2911-2916.
6. Chen MP, Chung FM, Chang DM et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299.
7. Ward AM, Fall CH, Stein CE et al. Cortisol and the metabolic syndrome in South Asians. Clin Endocrinol 2003; 58: 500-505.
8. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab 1982; 54: 131-138.
9. Kralisch S, Klein J, Lossner U et al. Hormonal regulation of novel adipocytokine visfatin in 3T3-L1 adipocytes. J Endocrinol 2005; 185: R1-R8.
10. WHO consultation: Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications. Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus. Geneva, WHO/NCD/NCS/99.2, World Health Org., 1999.
11. Matthews DR, Hosker JP, Rudensky AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
12. Arnaldi G, Angeli A, Atkinson AB et al. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593-5602.
13. Haider DG, Schinler K, Schaller G et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006; 91: 1578-1581.
14. Haider DG, Schaller G, Kapitis S et al. The release of the adipocytokine visfatin is regulated by glucose and insulin. Diabetologia 2006; 49: 1909-1914.
15. Jian W-X, Luo T-H, Gu Y-Y et al. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population. Diabetic Medicine 2006; 23: 967-973.
16. Pagano C, Pilon C, Olivieri M et al. Reduced plasma visfatin/pre b-cell colony enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrin Metab 2006; 91: 3165-3170.
17. Tan BK, Chen J, Digby JE et al. Increased visfatin mRNA and protein levels in adipose tissue and adipocytes in women with polycystic ovary syndrome (PCOS): parallel increase in plasma visfatin. J Clin Endocrinol Metab 2006; 91: 5022-5028.
18. Chan TF, Chen YL, Lee CH et al. Decreased plasma visfatin concentrations in women with gestational diabetes mellitus. J Soc Gynecol Invest 2006; 13: 364-367.
19. Krzyzanowska K, Krugluger W, Mittermayer F et al. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci 2006; 110: 605-609.
20. Lewandowski KC, Stojanovic N, Press M et al. Elevated serum levels of visfatin in gestational diabetes: a comparative study across various degrees of glucose tolerance. Diabetologia 2007; 50: 1033-1037.
21. Lewandowski KC, Szosland K, Lewinski A. Short-term dexamethasone administration does not alter serum adiponectin or resistin concentrations in overweight and obese subjects despite an increase in insulin resistance. Clin Endocrinol (Oxf) 2006; 65: 551-552.